BFM
TEVA icon

Boothbay Fund Management’s Teva Pharmaceuticals TEVA Stock Holding History

Boothbay Fund Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.26M Buy
+41,700
New +$1.34M 0.02% 826
2025
Q4 		– Sell
-58,600
Closed -$1.18M – 2360
2025
Q3 		$1.18M Hold
58,600
– – 0.02% 759
2025
Q2 		$982K Hold
58,600
– – 0.02% 686
2025
Q1 		$901K Buy
58,600
+29,700
+103% +$531K 0.02% 667
2024
Q4 		$637K Buy
+28,900
New +$526K 0.02% 791

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Boothbay Fund Management's TEVA Position: Q1 2026 in Review

Boothbay Fund Management reduced its Teva Pharmaceuticals (TEVA) stake by 22% in Q1 2026, selling an estimated $818K and leaving 88,379 shares worth $2.66M. The position accounts for 0.03% of the portfolio, ranked #513.

Boothbay Fund Management first reported a position in TEVA in Q1 2015 and has held it in 12 quarters since. The position peaked at $4.03M in Q3 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Boothbay Fund Management held 88,379 shares of Teva Pharmaceuticals worth $2.66M as of Q1 2026.
  • Boothbay Fund Management sold 25,434 Teva Pharmaceuticals shares in Q1 2026, an estimated $818K.
  • Teva Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #513 holding.
  • Boothbay Fund Management first reported a position in Teva Pharmaceuticals in Q1 2015 and has held it in 12 quarters since.
  • Boothbay Fund Management's Teva Pharmaceuticals position peaked at $4.03M in Q3 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.